A phase I clinical study of autologous dendritic cell therapy in patients with relapsed or refractory multiple myeloma
/in Dendritic Cells, International Publications, Multiple Myeloma /von 2017-06-20 / Oncotarget 2017 Jun;8(25):41538-41548Immunotherapy for Patients with Advanced Urothelial Cancer: Current Evidence and Future Perspectives
/in Checkpoint-Inhibitors, Dendritic Cells, International Publications, Urothelial Carcinoma /von 2017-06-07 / Biomed Res Int 2017;2017:5618174Influence of ovarian cancer type I and type II microenvironment on the phenotype and function of monocyte-derived dendritic cells
/in Dendritic Cells, International Publications, Ovarian Cancer /von 2017-06-06 / Clin Transl Oncol 2017 Dec;19(12):1489-1497Association of autologous AdHER2 dendritic cell vaccination with antitumor activity and number of circulating tumor cells.
/in Breast Cancer, Dendritic Cells, International Publications /von 2017-06-05 / J Clin Oncol 35, 2017 (suppl; abstr 3089)A phase III, double-blind, randomized clinical trial comparing S-1 in combination with DC vaccine loaded with WT1 peptides (TLP0-001) or placebo for the patients with advanced pancreatic cancer refractory to standard chemotherapy.
/in Dendritic Cells, International Publications, Pancreatic Cancer /von 2017-06-03 / J Clin Oncol 35, 2017 (suppl; abstr TPS4153)Evaluation of the oncolytic potential of RB Mukteshwar vaccine strain of Newcastle disease virus (NDV) in a colon cancer cell line (SW-620)
/in Colorectal Cancer, International Publications, Newcastle Disease Virus /von 2017-06-03 / Arch. Virol. 2017 Sep;162(9):2705-2713Immunotherapy in urothelial cancer, part 1: T-cell checkpoint inhibition in advanced or metastatic disease
/in International Publications, Newcastle Disease Virus, Urothelial Carcinoma /von 2017-06-01 / Clin Adv Hematol Oncol 2017 Jun;15(6):466-477Oncolytic Viruses in Cancer Treatment: A Review
/in International Publications, Newcastle Disease Virus /von 2017-06-01 / JAMA Oncol 2017 Jun;3(6):841-849Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma
/in Checkpoint-Inhibitors, Dendritic Cells, Glioblastoma, International Publications /von 2017-06-01 / Neuro-oncology 2017 06;19(6):796-807
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies
- Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
- Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution